nodes	percent_of_prediction	percent_of_DWPC	metapath
Bortezomib—CYP2C8—Simvastatin—atherosclerosis	0.0407	0.0764	CbGbCtD
Bortezomib—CYP2C8—Pravastatin—atherosclerosis	0.0399	0.0747	CbGbCtD
Bortezomib—CYP2C8—Lovastatin—atherosclerosis	0.0399	0.0747	CbGbCtD
Bortezomib—CYP2C19—Rosuvastatin—atherosclerosis	0.0368	0.0689	CbGbCtD
Bortezomib—CYP2C19—Simvastatin—atherosclerosis	0.0342	0.0641	CbGbCtD
Bortezomib—CYP2C19—Lovastatin—atherosclerosis	0.0335	0.0627	CbGbCtD
Bortezomib—CYP2D6—Niacin—atherosclerosis	0.0329	0.0616	CbGbCtD
Bortezomib—CYP2C9—Rosuvastatin—atherosclerosis	0.0306	0.0573	CbGbCtD
Bortezomib—CYP2C9—Simvastatin—atherosclerosis	0.0284	0.0533	CbGbCtD
Bortezomib—CYP2C9—Pravastatin—atherosclerosis	0.0278	0.0521	CbGbCtD
Bortezomib—CYP2C9—Lovastatin—atherosclerosis	0.0278	0.0521	CbGbCtD
Bortezomib—CYP2D6—Simvastatin—atherosclerosis	0.026	0.0487	CbGbCtD
Bortezomib—CYP2D6—Lovastatin—atherosclerosis	0.0254	0.0477	CbGbCtD
Bortezomib—CYP2D6—Pravastatin—atherosclerosis	0.0254	0.0477	CbGbCtD
Bortezomib—CYP3A4—Ezetimibe—atherosclerosis	0.0178	0.0333	CbGbCtD
Bortezomib—CYP3A4—Rosuvastatin—atherosclerosis	0.0178	0.0333	CbGbCtD
Bortezomib—CYP3A4—Simvastatin—atherosclerosis	0.0165	0.031	CbGbCtD
Bortezomib—CYP3A4—Lovastatin—atherosclerosis	0.0162	0.0303	CbGbCtD
Bortezomib—CYP3A4—Pravastatin—atherosclerosis	0.0162	0.0303	CbGbCtD
Bortezomib—CTSG—connective tissue—atherosclerosis	0.00384	0.064	CbGeAlD
Bortezomib—PSMD2—Pimozide—Ezetimibe—atherosclerosis	0.00376	0.67	CbGdCrCtD
Bortezomib—Aspartame—TRPV1—atherosclerosis	0.00376	0.781	CrCbGaD
Bortezomib—PSMA1—connective tissue—atherosclerosis	0.00368	0.0614	CbGeAlD
Bortezomib—CTSG—cardiovascular system—atherosclerosis	0.00334	0.0557	CbGeAlD
Bortezomib—PSMA1—cardiovascular system—atherosclerosis	0.0032	0.0535	CbGeAlD
Bortezomib—CTSG—adipose tissue—atherosclerosis	0.00294	0.0491	CbGeAlD
Bortezomib—PSMA1—adipose tissue—atherosclerosis	0.00283	0.0471	CbGeAlD
Bortezomib—PSMD2—cardiovascular system—atherosclerosis	0.00238	0.0398	CbGeAlD
Bortezomib—PSMD1—adipose tissue—atherosclerosis	0.00237	0.0396	CbGeAlD
Bortezomib—PSMD2—adipose tissue—atherosclerosis	0.0021	0.0351	CbGeAlD
Bortezomib—PSMB8—adipose tissue—atherosclerosis	0.00209	0.0348	CbGeAlD
Bortezomib—PSMB2—connective tissue—atherosclerosis	0.00205	0.0342	CbGeAlD
Bortezomib—PSMA1—liver—atherosclerosis	0.00198	0.0331	CbGeAlD
Bortezomib—PSMB8—Fluvastatin—Rosuvastatin—atherosclerosis	0.00185	0.33	CbGdCrCtD
Bortezomib—PSMB5—adipose tissue—atherosclerosis	0.00184	0.0308	CbGeAlD
Bortezomib—PSMB1—cardiovascular system—atherosclerosis	0.00183	0.0305	CbGeAlD
Bortezomib—PSMB2—cardiovascular system—atherosclerosis	0.00178	0.0298	CbGeAlD
Bortezomib—PSMD1—liver—atherosclerosis	0.00166	0.0278	CbGeAlD
Bortezomib—PSMB1—adipose tissue—atherosclerosis	0.00161	0.0269	CbGeAlD
Bortezomib—PSMB2—adipose tissue—atherosclerosis	0.00157	0.0263	CbGeAlD
Bortezomib—PSMD2—liver—atherosclerosis	0.00147	0.0246	CbGeAlD
Bortezomib—PSMB8—liver—atherosclerosis	0.00146	0.0244	CbGeAlD
Bortezomib—SLC31A1—adipose tissue—atherosclerosis	0.00136	0.0227	CbGeAlD
Bortezomib—PTGS1—artery—atherosclerosis	0.00133	0.0221	CbGeAlD
Bortezomib—PSMB5—liver—atherosclerosis	0.00129	0.0216	CbGeAlD
Bortezomib—PSMB1—liver—atherosclerosis	0.00113	0.0189	CbGeAlD
Bortezomib—PTGS1—endothelium—atherosclerosis	0.00112	0.0187	CbGeAlD
Bortezomib—PSMB2—liver—atherosclerosis	0.0011	0.0184	CbGeAlD
Bortezomib—PTGS1—blood vessel—atherosclerosis	0.00103	0.0172	CbGeAlD
Bortezomib—SLC31A1—liver—atherosclerosis	0.000955	0.0159	CbGeAlD
Bortezomib—Nateglinide—PPARG—atherosclerosis	0.000767	0.159	CrCbGaD
Bortezomib—PTGS1—connective tissue—atherosclerosis	0.00053	0.00884	CbGeAlD
Bortezomib—CYP2C9—cardiovascular system—atherosclerosis	0.000505	0.00843	CbGeAlD
Bortezomib—CYP1A1—adipose tissue—atherosclerosis	0.000463	0.00772	CbGeAlD
Bortezomib—PTGS1—cardiovascular system—atherosclerosis	0.000461	0.00769	CbGeAlD
Bortezomib—PTGS1—adipose tissue—atherosclerosis	0.000406	0.00678	CbGeAlD
Bortezomib—CYP2C19—liver—atherosclerosis	0.000403	0.00672	CbGeAlD
Bortezomib—CYP2C8—liver—atherosclerosis	0.000352	0.00587	CbGeAlD
Bortezomib—CYP1A2—liver—atherosclerosis	0.000329	0.00549	CbGeAlD
Bortezomib—CYP1A1—liver—atherosclerosis	0.000324	0.00541	CbGeAlD
Bortezomib—CYP2C9—liver—atherosclerosis	0.000312	0.00521	CbGeAlD
Bortezomib—Nateglinide—ALB—atherosclerosis	0.000289	0.0599	CrCbGaD
Bortezomib—Erythema multiforme—Pravastatin—atherosclerosis	0.000279	0.00127	CcSEcCtD
Bortezomib—Dysgeusia—Simvastatin—atherosclerosis	0.000278	0.00127	CcSEcCtD
Bortezomib—Flushing—Niacin—atherosclerosis	0.000278	0.00127	CcSEcCtD
Bortezomib—Angioedema—Lovastatin—atherosclerosis	0.000278	0.00126	CcSEcCtD
Bortezomib—Ill-defined disorder—Ezetimibe—atherosclerosis	0.000277	0.00126	CcSEcCtD
Bortezomib—Anaemia—Ezetimibe—atherosclerosis	0.000276	0.00125	CcSEcCtD
Bortezomib—Tinnitus—Pravastatin—atherosclerosis	0.000275	0.00125	CcSEcCtD
Bortezomib—Malaise—Lovastatin—atherosclerosis	0.000274	0.00125	CcSEcCtD
Bortezomib—Cardiac disorder—Pravastatin—atherosclerosis	0.000274	0.00125	CcSEcCtD
Bortezomib—Flushing—Pravastatin—atherosclerosis	0.000274	0.00125	CcSEcCtD
Bortezomib—Muscle spasms—Simvastatin—atherosclerosis	0.000273	0.00124	CcSEcCtD
Bortezomib—Vertigo—Lovastatin—atherosclerosis	0.000273	0.00124	CcSEcCtD
Bortezomib—Angioedema—Ezetimibe—atherosclerosis	0.000272	0.00124	CcSEcCtD
Bortezomib—Angiopathy—Niacin—atherosclerosis	0.000272	0.00124	CcSEcCtD
Bortezomib—Leukopenia—Lovastatin—atherosclerosis	0.000272	0.00124	CcSEcCtD
Bortezomib—Chills—Niacin—atherosclerosis	0.000269	0.00122	CcSEcCtD
Bortezomib—Malaise—Ezetimibe—atherosclerosis	0.000269	0.00122	CcSEcCtD
Bortezomib—Vision blurred—Simvastatin—atherosclerosis	0.000268	0.00122	CcSEcCtD
Bortezomib—Arrhythmia—Niacin—atherosclerosis	0.000268	0.00122	CcSEcCtD
Bortezomib—Musculoskeletal discomfort—Rosuvastatin—atherosclerosis	0.000267	0.00121	CcSEcCtD
Bortezomib—Tremor—Simvastatin—atherosclerosis	0.000266	0.00121	CcSEcCtD
Bortezomib—Chills—Pravastatin—atherosclerosis	0.000265	0.0012	CcSEcCtD
Bortezomib—Insomnia—Rosuvastatin—atherosclerosis	0.000265	0.0012	CcSEcCtD
Bortezomib—Ill-defined disorder—Simvastatin—atherosclerosis	0.000264	0.0012	CcSEcCtD
Bortezomib—Arrhythmia—Pravastatin—atherosclerosis	0.000264	0.0012	CcSEcCtD
Bortezomib—Palpitations—Ezetimibe—atherosclerosis	0.000263	0.0012	CcSEcCtD
Bortezomib—Paraesthesia—Rosuvastatin—atherosclerosis	0.000263	0.0012	CcSEcCtD
Bortezomib—Anaemia—Simvastatin—atherosclerosis	0.000263	0.0012	CcSEcCtD
Bortezomib—Erythema—Niacin—atherosclerosis	0.000261	0.00119	CcSEcCtD
Bortezomib—Malnutrition—Niacin—atherosclerosis	0.000261	0.00119	CcSEcCtD
Bortezomib—Cough—Ezetimibe—atherosclerosis	0.00026	0.00118	CcSEcCtD
Bortezomib—Angioedema—Simvastatin—atherosclerosis	0.00026	0.00118	CcSEcCtD
Bortezomib—Arthralgia—Lovastatin—atherosclerosis	0.000259	0.00118	CcSEcCtD
Bortezomib—Chest pain—Lovastatin—atherosclerosis	0.000259	0.00118	CcSEcCtD
Bortezomib—Myalgia—Lovastatin—atherosclerosis	0.000259	0.00118	CcSEcCtD
Bortezomib—Anxiety—Lovastatin—atherosclerosis	0.000258	0.00117	CcSEcCtD
Bortezomib—Dyspepsia—Rosuvastatin—atherosclerosis	0.000258	0.00117	CcSEcCtD
Bortezomib—Hypertension—Ezetimibe—atherosclerosis	0.000257	0.00117	CcSEcCtD
Bortezomib—Flatulence—Niacin—atherosclerosis	0.000257	0.00117	CcSEcCtD
Bortezomib—Malaise—Simvastatin—atherosclerosis	0.000256	0.00117	CcSEcCtD
Bortezomib—Discomfort—Lovastatin—atherosclerosis	0.000256	0.00116	CcSEcCtD
Bortezomib—Vertigo—Simvastatin—atherosclerosis	0.000255	0.00116	CcSEcCtD
Bortezomib—Leukopenia—Simvastatin—atherosclerosis	0.000255	0.00116	CcSEcCtD
Bortezomib—Myalgia—Ezetimibe—atherosclerosis	0.000254	0.00115	CcSEcCtD
Bortezomib—Chest pain—Ezetimibe—atherosclerosis	0.000254	0.00115	CcSEcCtD
Bortezomib—Arthralgia—Ezetimibe—atherosclerosis	0.000254	0.00115	CcSEcCtD
Bortezomib—Flatulence—Pravastatin—atherosclerosis	0.000253	0.00115	CcSEcCtD
Bortezomib—Unspecified disorder of skin and subcutaneous tissue—Ezetimibe—atherosclerosis	0.000252	0.00115	CcSEcCtD
Bortezomib—Dysgeusia—Pravastatin—atherosclerosis	0.000252	0.00114	CcSEcCtD
Bortezomib—Muscle spasms—Niacin—atherosclerosis	0.000251	0.00114	CcSEcCtD
Bortezomib—Discomfort—Ezetimibe—atherosclerosis	0.000251	0.00114	CcSEcCtD
Bortezomib—Pain—Rosuvastatin—atherosclerosis	0.00025	0.00114	CcSEcCtD
Bortezomib—Constipation—Rosuvastatin—atherosclerosis	0.00025	0.00114	CcSEcCtD
Bortezomib—Confusional state—Lovastatin—atherosclerosis	0.00025	0.00114	CcSEcCtD
Bortezomib—Anaphylactic shock—Lovastatin—atherosclerosis	0.000248	0.00113	CcSEcCtD
Bortezomib—Muscle spasms—Pravastatin—atherosclerosis	0.000247	0.00112	CcSEcCtD
Bortezomib—Infection—Lovastatin—atherosclerosis	0.000246	0.00112	CcSEcCtD
Bortezomib—Vision blurred—Niacin—atherosclerosis	0.000246	0.00112	CcSEcCtD
Bortezomib—Confusional state—Ezetimibe—atherosclerosis	0.000245	0.00112	CcSEcCtD
Bortezomib—Anaphylactic shock—Ezetimibe—atherosclerosis	0.000243	0.00111	CcSEcCtD
Bortezomib—Thrombocytopenia—Lovastatin—atherosclerosis	0.000243	0.0011	CcSEcCtD
Bortezomib—Vision blurred—Pravastatin—atherosclerosis	0.000242	0.0011	CcSEcCtD
Bortezomib—Chest pain—Simvastatin—atherosclerosis	0.000242	0.0011	CcSEcCtD
Bortezomib—Arthralgia—Simvastatin—atherosclerosis	0.000242	0.0011	CcSEcCtD
Bortezomib—Myalgia—Simvastatin—atherosclerosis	0.000242	0.0011	CcSEcCtD
Bortezomib—Infection—Ezetimibe—atherosclerosis	0.000242	0.0011	CcSEcCtD
Bortezomib—Feeling abnormal—Rosuvastatin—atherosclerosis	0.000241	0.0011	CcSEcCtD
Bortezomib—Anxiety—Simvastatin—atherosclerosis	0.000241	0.0011	CcSEcCtD
Bortezomib—Tremor—Pravastatin—atherosclerosis	0.000241	0.0011	CcSEcCtD
Bortezomib—Gastrointestinal pain—Rosuvastatin—atherosclerosis	0.000239	0.00109	CcSEcCtD
Bortezomib—Discomfort—Simvastatin—atherosclerosis	0.000239	0.00109	CcSEcCtD
Bortezomib—Nervous system disorder—Ezetimibe—atherosclerosis	0.000239	0.00109	CcSEcCtD
Bortezomib—Angioedema—Niacin—atherosclerosis	0.000239	0.00108	CcSEcCtD
Bortezomib—Ill-defined disorder—Pravastatin—atherosclerosis	0.000239	0.00108	CcSEcCtD
Bortezomib—Thrombocytopenia—Ezetimibe—atherosclerosis	0.000238	0.00108	CcSEcCtD
Bortezomib—CYP3A4—liver—atherosclerosis	0.000238	0.00397	CbGeAlD
Bortezomib—Anaemia—Pravastatin—atherosclerosis	0.000238	0.00108	CcSEcCtD
Bortezomib—Anorexia—Lovastatin—atherosclerosis	0.000236	0.00108	CcSEcCtD
Bortezomib—Skin disorder—Ezetimibe—atherosclerosis	0.000236	0.00107	CcSEcCtD
Bortezomib—Angioedema—Pravastatin—atherosclerosis	0.000235	0.00107	CcSEcCtD
Bortezomib—Vertigo—Niacin—atherosclerosis	0.000235	0.00107	CcSEcCtD
Bortezomib—CYP2D6—liver—atherosclerosis	0.000234	0.00391	CbGeAlD
Bortezomib—Syncope—Niacin—atherosclerosis	0.000234	0.00106	CcSEcCtD
Bortezomib—Confusional state—Simvastatin—atherosclerosis	0.000234	0.00106	CcSEcCtD
Bortezomib—Leukopenia—Niacin—atherosclerosis	0.000234	0.00106	CcSEcCtD
Bortezomib—Urticaria—Rosuvastatin—atherosclerosis	0.000233	0.00106	CcSEcCtD
Bortezomib—Anaphylactic shock—Simvastatin—atherosclerosis	0.000232	0.00106	CcSEcCtD
Bortezomib—Oedema—Simvastatin—atherosclerosis	0.000232	0.00106	CcSEcCtD
Bortezomib—Malaise—Pravastatin—atherosclerosis	0.000232	0.00105	CcSEcCtD
Bortezomib—Abdominal pain—Rosuvastatin—atherosclerosis	0.000231	0.00105	CcSEcCtD
Bortezomib—Vertigo—Pravastatin—atherosclerosis	0.000231	0.00105	CcSEcCtD
Bortezomib—Palpitations—Niacin—atherosclerosis	0.000231	0.00105	CcSEcCtD
Bortezomib—Infection—Simvastatin—atherosclerosis	0.000231	0.00105	CcSEcCtD
Bortezomib—Leukopenia—Pravastatin—atherosclerosis	0.00023	0.00105	CcSEcCtD
Bortezomib—Loss of consciousness—Niacin—atherosclerosis	0.000229	0.00104	CcSEcCtD
Bortezomib—Cough—Niacin—atherosclerosis	0.000228	0.00104	CcSEcCtD
Bortezomib—Thrombocytopenia—Simvastatin—atherosclerosis	0.000227	0.00103	CcSEcCtD
Bortezomib—Musculoskeletal discomfort—Lovastatin—atherosclerosis	0.000226	0.00103	CcSEcCtD
Bortezomib—Insomnia—Lovastatin—atherosclerosis	0.000224	0.00102	CcSEcCtD
Bortezomib—Cough—Pravastatin—atherosclerosis	0.000224	0.00102	CcSEcCtD
Bortezomib—Paraesthesia—Lovastatin—atherosclerosis	0.000223	0.00101	CcSEcCtD
Bortezomib—Myalgia—Niacin—atherosclerosis	0.000222	0.00101	CcSEcCtD
Bortezomib—Arthralgia—Niacin—atherosclerosis	0.000222	0.00101	CcSEcCtD
Bortezomib—Hypertension—Pravastatin—atherosclerosis	0.000222	0.00101	CcSEcCtD
Bortezomib—Musculoskeletal discomfort—Ezetimibe—atherosclerosis	0.000222	0.00101	CcSEcCtD
Bortezomib—Anorexia—Simvastatin—atherosclerosis	0.000221	0.00101	CcSEcCtD
Bortezomib—Dyspnoea—Lovastatin—atherosclerosis	0.000221	0.00101	CcSEcCtD
Bortezomib—Unspecified disorder of skin and subcutaneous tissue—Niacin—atherosclerosis	0.000221	0.001	CcSEcCtD
Bortezomib—Insomnia—Ezetimibe—atherosclerosis	0.00022	0.001	CcSEcCtD
Bortezomib—Arthralgia—Pravastatin—atherosclerosis	0.000219	0.000995	CcSEcCtD
Bortezomib—Myalgia—Pravastatin—atherosclerosis	0.000219	0.000995	CcSEcCtD
Bortezomib—Chest pain—Pravastatin—atherosclerosis	0.000219	0.000995	CcSEcCtD
Bortezomib—Paraesthesia—Ezetimibe—atherosclerosis	0.000218	0.000994	CcSEcCtD
Bortezomib—Dyspepsia—Lovastatin—atherosclerosis	0.000218	0.000993	CcSEcCtD
Bortezomib—Anxiety—Pravastatin—atherosclerosis	0.000218	0.000992	CcSEcCtD
Bortezomib—Dyspnoea—Ezetimibe—atherosclerosis	0.000217	0.000987	CcSEcCtD
Bortezomib—Discomfort—Pravastatin—atherosclerosis	0.000216	0.000983	CcSEcCtD
Bortezomib—Hypersensitivity—Rosuvastatin—atherosclerosis	0.000216	0.000981	CcSEcCtD
Bortezomib—Decreased appetite—Lovastatin—atherosclerosis	0.000216	0.000981	CcSEcCtD
Bortezomib—Dyspepsia—Ezetimibe—atherosclerosis	0.000214	0.000974	CcSEcCtD
Bortezomib—Fatigue—Lovastatin—atherosclerosis	0.000214	0.000973	CcSEcCtD
Bortezomib—Anaphylactic shock—Niacin—atherosclerosis	0.000213	0.000969	CcSEcCtD
Bortezomib—Oedema—Niacin—atherosclerosis	0.000213	0.000969	CcSEcCtD
Bortezomib—Constipation—Lovastatin—atherosclerosis	0.000212	0.000965	CcSEcCtD
Bortezomib—Pain—Lovastatin—atherosclerosis	0.000212	0.000965	CcSEcCtD
Bortezomib—Confusional state—Pravastatin—atherosclerosis	0.000212	0.000962	CcSEcCtD
Bortezomib—Decreased appetite—Ezetimibe—atherosclerosis	0.000212	0.000962	CcSEcCtD
Bortezomib—Musculoskeletal discomfort—Simvastatin—atherosclerosis	0.000211	0.000961	CcSEcCtD
Bortezomib—Gastrointestinal disorder—Ezetimibe—atherosclerosis	0.00021	0.000955	CcSEcCtD
Bortezomib—Asthenia—Rosuvastatin—atherosclerosis	0.00021	0.000955	CcSEcCtD
Bortezomib—Insomnia—Simvastatin—atherosclerosis	0.00021	0.000954	CcSEcCtD
Bortezomib—Oedema—Pravastatin—atherosclerosis	0.00021	0.000954	CcSEcCtD
Bortezomib—Anaphylactic shock—Pravastatin—atherosclerosis	0.00021	0.000954	CcSEcCtD
Bortezomib—Fatigue—Ezetimibe—atherosclerosis	0.00021	0.000954	CcSEcCtD
Bortezomib—Shock—Niacin—atherosclerosis	0.00021	0.000953	CcSEcCtD
Bortezomib—Infection—Pravastatin—atherosclerosis	0.000208	0.000948	CcSEcCtD
Bortezomib—Paraesthesia—Simvastatin—atherosclerosis	0.000208	0.000948	CcSEcCtD
Bortezomib—Pain—Ezetimibe—atherosclerosis	0.000208	0.000946	CcSEcCtD
Bortezomib—Constipation—Ezetimibe—atherosclerosis	0.000208	0.000946	CcSEcCtD
Bortezomib—Tachycardia—Niacin—atherosclerosis	0.000208	0.000946	CcSEcCtD
Bortezomib—Pruritus—Rosuvastatin—atherosclerosis	0.000207	0.000942	CcSEcCtD
Bortezomib—Skin disorder—Niacin—atherosclerosis	0.000207	0.000941	CcSEcCtD
Bortezomib—Dyspnoea—Simvastatin—atherosclerosis	0.000207	0.000941	CcSEcCtD
Bortezomib—Hyperhidrosis—Niacin—atherosclerosis	0.000206	0.000937	CcSEcCtD
Bortezomib—Thrombocytopenia—Pravastatin—atherosclerosis	0.000205	0.000934	CcSEcCtD
Bortezomib—Feeling abnormal—Lovastatin—atherosclerosis	0.000204	0.00093	CcSEcCtD
Bortezomib—Dyspepsia—Simvastatin—atherosclerosis	0.000204	0.000929	CcSEcCtD
Bortezomib—Anorexia—Niacin—atherosclerosis	0.000203	0.000924	CcSEcCtD
Bortezomib—Gastrointestinal pain—Lovastatin—atherosclerosis	0.000203	0.000923	CcSEcCtD
Bortezomib—Hyperhidrosis—Pravastatin—atherosclerosis	0.000203	0.000922	CcSEcCtD
Bortezomib—Decreased appetite—Simvastatin—atherosclerosis	0.000202	0.000917	CcSEcCtD
Bortezomib—Feeling abnormal—Ezetimibe—atherosclerosis	0.000201	0.000912	CcSEcCtD
Bortezomib—Gastrointestinal disorder—Simvastatin—atherosclerosis	0.0002	0.000911	CcSEcCtD
Bortezomib—Diarrhoea—Rosuvastatin—atherosclerosis	0.0002	0.000911	CcSEcCtD
Bortezomib—Fatigue—Simvastatin—atherosclerosis	0.0002	0.00091	CcSEcCtD
Bortezomib—Anorexia—Pravastatin—atherosclerosis	0.0002	0.000909	CcSEcCtD
Bortezomib—Hypotension—Niacin—atherosclerosis	0.000199	0.000905	CcSEcCtD
Bortezomib—Gastrointestinal pain—Ezetimibe—atherosclerosis	0.000199	0.000905	CcSEcCtD
Bortezomib—Pain—Simvastatin—atherosclerosis	0.000198	0.000902	CcSEcCtD
Bortezomib—Constipation—Simvastatin—atherosclerosis	0.000198	0.000902	CcSEcCtD
Bortezomib—Urticaria—Lovastatin—atherosclerosis	0.000197	0.000896	CcSEcCtD
Bortezomib—Abdominal pain—Lovastatin—atherosclerosis	0.000196	0.000892	CcSEcCtD
Bortezomib—Body temperature increased—Lovastatin—atherosclerosis	0.000196	0.000892	CcSEcCtD
Bortezomib—Musculoskeletal discomfort—Niacin—atherosclerosis	0.000194	0.000883	CcSEcCtD
Bortezomib—Dizziness—Rosuvastatin—atherosclerosis	0.000194	0.00088	CcSEcCtD
Bortezomib—Urticaria—Ezetimibe—atherosclerosis	0.000193	0.000879	CcSEcCtD
Bortezomib—Insomnia—Niacin—atherosclerosis	0.000193	0.000876	CcSEcCtD
Bortezomib—Abdominal pain—Ezetimibe—atherosclerosis	0.000192	0.000875	CcSEcCtD
Bortezomib—Body temperature increased—Ezetimibe—atherosclerosis	0.000192	0.000875	CcSEcCtD
Bortezomib—Paraesthesia—Niacin—atherosclerosis	0.000191	0.00087	CcSEcCtD
Bortezomib—Feeling abnormal—Simvastatin—atherosclerosis	0.000191	0.00087	CcSEcCtD
Bortezomib—Musculoskeletal discomfort—Pravastatin—atherosclerosis	0.000191	0.000869	CcSEcCtD
Bortezomib—Dyspnoea—Niacin—atherosclerosis	0.00019	0.000864	CcSEcCtD
Bortezomib—Gastrointestinal pain—Simvastatin—atherosclerosis	0.00019	0.000863	CcSEcCtD
Bortezomib—Insomnia—Pravastatin—atherosclerosis	0.00019	0.000863	CcSEcCtD
Bortezomib—Paraesthesia—Pravastatin—atherosclerosis	0.000188	0.000857	CcSEcCtD
Bortezomib—Dyspepsia—Niacin—atherosclerosis	0.000188	0.000853	CcSEcCtD
Bortezomib—Dyspnoea—Pravastatin—atherosclerosis	0.000187	0.000851	CcSEcCtD
Bortezomib—Decreased appetite—Niacin—atherosclerosis	0.000185	0.000842	CcSEcCtD
Bortezomib—Dyspepsia—Pravastatin—atherosclerosis	0.000185	0.00084	CcSEcCtD
Bortezomib—Rash—Rosuvastatin—atherosclerosis	0.000185	0.000839	CcSEcCtD
Bortezomib—Dermatitis—Rosuvastatin—atherosclerosis	0.000184	0.000839	CcSEcCtD
Bortezomib—Urticaria—Simvastatin—atherosclerosis	0.000184	0.000838	CcSEcCtD
Bortezomib—Gastrointestinal disorder—Niacin—atherosclerosis	0.000184	0.000837	CcSEcCtD
Bortezomib—Body temperature increased—Simvastatin—atherosclerosis	0.000183	0.000834	CcSEcCtD
Bortezomib—Abdominal pain—Simvastatin—atherosclerosis	0.000183	0.000834	CcSEcCtD
Bortezomib—Headache—Rosuvastatin—atherosclerosis	0.000183	0.000834	CcSEcCtD
Bortezomib—Hypersensitivity—Lovastatin—atherosclerosis	0.000183	0.000831	CcSEcCtD
Bortezomib—Decreased appetite—Pravastatin—atherosclerosis	0.000182	0.000829	CcSEcCtD
Bortezomib—Pain—Niacin—atherosclerosis	0.000182	0.000829	CcSEcCtD
Bortezomib—Fatigue—Pravastatin—atherosclerosis	0.000181	0.000823	CcSEcCtD
Bortezomib—Pain—Pravastatin—atherosclerosis	0.000179	0.000816	CcSEcCtD
Bortezomib—Constipation—Pravastatin—atherosclerosis	0.000179	0.000816	CcSEcCtD
Bortezomib—Hypersensitivity—Ezetimibe—atherosclerosis	0.000179	0.000815	CcSEcCtD
Bortezomib—Asthenia—Lovastatin—atherosclerosis	0.000178	0.000809	CcSEcCtD
Bortezomib—Pruritus—Lovastatin—atherosclerosis	0.000176	0.000798	CcSEcCtD
Bortezomib—Asthenia—Ezetimibe—atherosclerosis	0.000175	0.000794	CcSEcCtD
Bortezomib—Gastrointestinal pain—Niacin—atherosclerosis	0.000174	0.000792	CcSEcCtD
Bortezomib—Nausea—Rosuvastatin—atherosclerosis	0.000174	0.000791	CcSEcCtD
Bortezomib—Feeling abnormal—Pravastatin—atherosclerosis	0.000173	0.000786	CcSEcCtD
Bortezomib—Pruritus—Ezetimibe—atherosclerosis	0.000172	0.000783	CcSEcCtD
Bortezomib—Gastrointestinal pain—Pravastatin—atherosclerosis	0.000172	0.00078	CcSEcCtD
Bortezomib—Hypersensitivity—Simvastatin—atherosclerosis	0.000171	0.000777	CcSEcCtD
Bortezomib—Diarrhoea—Lovastatin—atherosclerosis	0.00017	0.000772	CcSEcCtD
Bortezomib—Urticaria—Niacin—atherosclerosis	0.000169	0.00077	CcSEcCtD
Bortezomib—Abdominal pain—Niacin—atherosclerosis	0.000168	0.000766	CcSEcCtD
Bortezomib—Body temperature increased—Niacin—atherosclerosis	0.000168	0.000766	CcSEcCtD
Bortezomib—Urticaria—Pravastatin—atherosclerosis	0.000167	0.000758	CcSEcCtD
Bortezomib—Asthenia—Simvastatin—atherosclerosis	0.000166	0.000757	CcSEcCtD
Bortezomib—Diarrhoea—Ezetimibe—atherosclerosis	0.000166	0.000757	CcSEcCtD
Bortezomib—Abdominal pain—Pravastatin—atherosclerosis	0.000166	0.000754	CcSEcCtD
Bortezomib—Body temperature increased—Pravastatin—atherosclerosis	0.000166	0.000754	CcSEcCtD
Bortezomib—Pruritus—Simvastatin—atherosclerosis	0.000164	0.000747	CcSEcCtD
Bortezomib—Dizziness—Lovastatin—atherosclerosis	0.000164	0.000746	CcSEcCtD
Bortezomib—Dizziness—Ezetimibe—atherosclerosis	0.000161	0.000732	CcSEcCtD
Bortezomib—Diarrhoea—Simvastatin—atherosclerosis	0.000159	0.000722	CcSEcCtD
Bortezomib—Vomiting—Lovastatin—atherosclerosis	0.000158	0.000717	CcSEcCtD
Bortezomib—Hypersensitivity—Niacin—atherosclerosis	0.000157	0.000714	CcSEcCtD
Bortezomib—Rash—Lovastatin—atherosclerosis	0.000156	0.000711	CcSEcCtD
Bortezomib—Dermatitis—Lovastatin—atherosclerosis	0.000156	0.000711	CcSEcCtD
Bortezomib—Headache—Lovastatin—atherosclerosis	0.000155	0.000707	CcSEcCtD
Bortezomib—Vomiting—Ezetimibe—atherosclerosis	0.000155	0.000704	CcSEcCtD
Bortezomib—Hypersensitivity—Pravastatin—atherosclerosis	0.000155	0.000703	CcSEcCtD
Bortezomib—Dizziness—Simvastatin—atherosclerosis	0.000153	0.000698	CcSEcCtD
Bortezomib—Rash—Ezetimibe—atherosclerosis	0.000153	0.000698	CcSEcCtD
Bortezomib—Dermatitis—Ezetimibe—atherosclerosis	0.000153	0.000697	CcSEcCtD
Bortezomib—Asthenia—Niacin—atherosclerosis	0.000153	0.000695	CcSEcCtD
Bortezomib—Headache—Ezetimibe—atherosclerosis	0.000152	0.000693	CcSEcCtD
Bortezomib—Pruritus—Niacin—atherosclerosis	0.000151	0.000686	CcSEcCtD
Bortezomib—Asthenia—Pravastatin—atherosclerosis	0.000151	0.000684	CcSEcCtD
Bortezomib—Pruritus—Pravastatin—atherosclerosis	0.000148	0.000675	CcSEcCtD
Bortezomib—Vomiting—Simvastatin—atherosclerosis	0.000148	0.000671	CcSEcCtD
Bortezomib—Nausea—Lovastatin—atherosclerosis	0.000147	0.00067	CcSEcCtD
Bortezomib—Rash—Simvastatin—atherosclerosis	0.000146	0.000665	CcSEcCtD
Bortezomib—Dermatitis—Simvastatin—atherosclerosis	0.000146	0.000665	CcSEcCtD
Bortezomib—Diarrhoea—Niacin—atherosclerosis	0.000146	0.000663	CcSEcCtD
Bortezomib—Headache—Simvastatin—atherosclerosis	0.000145	0.000661	CcSEcCtD
Bortezomib—Nausea—Ezetimibe—atherosclerosis	0.000145	0.000657	CcSEcCtD
Bortezomib—Diarrhoea—Pravastatin—atherosclerosis	0.000144	0.000653	CcSEcCtD
Bortezomib—Dizziness—Niacin—atherosclerosis	0.000141	0.000641	CcSEcCtD
Bortezomib—Dizziness—Pravastatin—atherosclerosis	0.000139	0.000631	CcSEcCtD
Bortezomib—Nausea—Simvastatin—atherosclerosis	0.000138	0.000627	CcSEcCtD
Bortezomib—Vomiting—Niacin—atherosclerosis	0.000135	0.000616	CcSEcCtD
Bortezomib—Rash—Niacin—atherosclerosis	0.000134	0.000611	CcSEcCtD
Bortezomib—Dermatitis—Niacin—atherosclerosis	0.000134	0.00061	CcSEcCtD
Bortezomib—Headache—Niacin—atherosclerosis	0.000133	0.000607	CcSEcCtD
Bortezomib—Vomiting—Pravastatin—atherosclerosis	0.000133	0.000607	CcSEcCtD
Bortezomib—Rash—Pravastatin—atherosclerosis	0.000132	0.000602	CcSEcCtD
Bortezomib—Dermatitis—Pravastatin—atherosclerosis	0.000132	0.000601	CcSEcCtD
Bortezomib—Headache—Pravastatin—atherosclerosis	0.000131	0.000598	CcSEcCtD
Bortezomib—Nausea—Niacin—atherosclerosis	0.000127	0.000576	CcSEcCtD
Bortezomib—Nausea—Pravastatin—atherosclerosis	0.000125	0.000567	CcSEcCtD
Bortezomib—PSMB1—Signaling Pathways—MMP9—atherosclerosis	7.53e-06	4.28e-05	CbGpPWpGaD
Bortezomib—PSMB5—Signaling Pathways—MMP9—atherosclerosis	7.53e-06	4.28e-05	CbGpPWpGaD
Bortezomib—PSMB2—Signaling Pathways—MMP9—atherosclerosis	7.53e-06	4.28e-05	CbGpPWpGaD
Bortezomib—CYP2D6—Metabolism—SCARB1—atherosclerosis	7.5e-06	4.26e-05	CbGpPWpGaD
Bortezomib—PSMB5—Signaling Pathways—NFKB1—atherosclerosis	7.45e-06	4.23e-05	CbGpPWpGaD
Bortezomib—PSMB1—Signaling Pathways—NFKB1—atherosclerosis	7.45e-06	4.23e-05	CbGpPWpGaD
Bortezomib—PSMB2—Signaling Pathways—NFKB1—atherosclerosis	7.45e-06	4.23e-05	CbGpPWpGaD
Bortezomib—CYP2C9—Metabolism—SCARB1—atherosclerosis	7.44e-06	4.22e-05	CbGpPWpGaD
Bortezomib—PSMB8—Signaling Pathways—MMP9—atherosclerosis	7.42e-06	4.22e-05	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—CYP27A1—atherosclerosis	7.39e-06	4.2e-05	CbGpPWpGaD
Bortezomib—PSMB8—Signaling Pathways—NFKB1—atherosclerosis	7.35e-06	4.17e-05	CbGpPWpGaD
Bortezomib—PSMB2—Signaling Pathways—MAPK8—atherosclerosis	7.32e-06	4.16e-05	CbGpPWpGaD
Bortezomib—PSMB5—Signaling Pathways—MAPK8—atherosclerosis	7.32e-06	4.16e-05	CbGpPWpGaD
Bortezomib—PSMB1—Signaling Pathways—MAPK8—atherosclerosis	7.32e-06	4.16e-05	CbGpPWpGaD
Bortezomib—CYP2C9—Metabolism of lipids and lipoproteins—ALB—atherosclerosis	7.24e-06	4.11e-05	CbGpPWpGaD
Bortezomib—PSMB2—Immune System—IL6—atherosclerosis	7.23e-06	4.11e-05	CbGpPWpGaD
Bortezomib—PSMB5—Immune System—IL6—atherosclerosis	7.23e-06	4.11e-05	CbGpPWpGaD
Bortezomib—PSMB1—Immune System—IL6—atherosclerosis	7.23e-06	4.11e-05	CbGpPWpGaD
Bortezomib—PSMB8—Signaling Pathways—MAPK8—atherosclerosis	7.22e-06	4.1e-05	CbGpPWpGaD
Bortezomib—CYP1A1—Metabolism—HMOX1—atherosclerosis	7.2e-06	4.09e-05	CbGpPWpGaD
Bortezomib—PSMB8—Immune System—IL6—atherosclerosis	7.13e-06	4.05e-05	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CG—atherosclerosis	7.13e-06	4.05e-05	CbGpPWpGaD
Bortezomib—CYP2D6—Metabolism—HMGCR—atherosclerosis	7.09e-06	4.02e-05	CbGpPWpGaD
Bortezomib—PTGS1—Metabolism—PIK3CG—atherosclerosis	7.07e-06	4.01e-05	CbGpPWpGaD
Bortezomib—CYP2C9—Metabolism—HMGCR—atherosclerosis	7.02e-06	3.99e-05	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—ALOX15—atherosclerosis	7.01e-06	3.98e-05	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—ALOX5AP—atherosclerosis	7.01e-06	3.98e-05	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—PLA2G2A—atherosclerosis	7.01e-06	3.98e-05	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—APOA2—atherosclerosis	7.01e-06	3.98e-05	CbGpPWpGaD
Bortezomib—CYP2C19—Metabolism of lipids and lipoproteins—PTGS2—atherosclerosis	6.95e-06	3.95e-05	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism—NAMPT—atherosclerosis	6.92e-06	3.93e-05	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—ABCG5—atherosclerosis	6.92e-06	3.93e-05	CbGpPWpGaD
Bortezomib—CYP1A1—Metabolism—APOB—atherosclerosis	6.9e-06	3.91e-05	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism of lipids and lipoproteins—PPARG—atherosclerosis	6.88e-06	3.91e-05	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism—LIPC—atherosclerosis	6.88e-06	3.91e-05	CbGpPWpGaD
Bortezomib—CYP2C19—Metabolism—ABCA1—atherosclerosis	6.87e-06	3.9e-05	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism—APOC3—atherosclerosis	6.84e-06	3.88e-05	CbGpPWpGaD
Bortezomib—PTGS1—Metabolism—PPARG—atherosclerosis	6.82e-06	3.87e-05	CbGpPWpGaD
Bortezomib—PSMA1—Metabolism—AKT1—atherosclerosis	6.81e-06	3.87e-05	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism—LDLR—atherosclerosis	6.8e-06	3.86e-05	CbGpPWpGaD
Bortezomib—PSMD1—Metabolism—AKT1—atherosclerosis	6.78e-06	3.85e-05	CbGpPWpGaD
Bortezomib—PSMB1—Signaling Pathways—VEGFA—atherosclerosis	6.76e-06	3.84e-05	CbGpPWpGaD
Bortezomib—PSMB2—Signaling Pathways—VEGFA—atherosclerosis	6.76e-06	3.84e-05	CbGpPWpGaD
Bortezomib—PSMB5—Signaling Pathways—VEGFA—atherosclerosis	6.76e-06	3.84e-05	CbGpPWpGaD
Bortezomib—PSMD2—Metabolism—AKT1—atherosclerosis	6.74e-06	3.83e-05	CbGpPWpGaD
Bortezomib—CYP1A1—Metabolism—GSTM1—atherosclerosis	6.71e-06	3.81e-05	CbGpPWpGaD
Bortezomib—PSMB5—Signaling Pathways—STAT3—atherosclerosis	6.7e-06	3.8e-05	CbGpPWpGaD
Bortezomib—PSMB2—Signaling Pathways—STAT3—atherosclerosis	6.7e-06	3.8e-05	CbGpPWpGaD
Bortezomib—PSMB1—Signaling Pathways—STAT3—atherosclerosis	6.7e-06	3.8e-05	CbGpPWpGaD
Bortezomib—PTGS1—Metabolism—INS—atherosclerosis	6.69e-06	3.8e-05	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—LPA—atherosclerosis	6.68e-06	3.79e-05	CbGpPWpGaD
Bortezomib—PSMB5—Disease—IL6—atherosclerosis	6.68e-06	3.79e-05	CbGpPWpGaD
Bortezomib—PSMB2—Disease—IL6—atherosclerosis	6.68e-06	3.79e-05	CbGpPWpGaD
Bortezomib—PSMB1—Disease—IL6—atherosclerosis	6.68e-06	3.79e-05	CbGpPWpGaD
Bortezomib—PSMB1—Immune System—AKT1—atherosclerosis	6.67e-06	3.79e-05	CbGpPWpGaD
Bortezomib—PSMB5—Immune System—AKT1—atherosclerosis	6.67e-06	3.79e-05	CbGpPWpGaD
Bortezomib—PSMB2—Immune System—AKT1—atherosclerosis	6.67e-06	3.79e-05	CbGpPWpGaD
Bortezomib—PSMB8—Signaling Pathways—VEGFA—atherosclerosis	6.67e-06	3.79e-05	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism—CETP—atherosclerosis	6.64e-06	3.77e-05	CbGpPWpGaD
Bortezomib—PSMB1—Gene Expression—AKT1—atherosclerosis	6.64e-06	3.77e-05	CbGpPWpGaD
Bortezomib—PSMB5—Gene Expression—AKT1—atherosclerosis	6.64e-06	3.77e-05	CbGpPWpGaD
Bortezomib—PSMB2—Gene Expression—AKT1—atherosclerosis	6.64e-06	3.77e-05	CbGpPWpGaD
Bortezomib—PSMB8—Signaling Pathways—STAT3—atherosclerosis	6.6e-06	3.75e-05	CbGpPWpGaD
Bortezomib—CYP2C8—Metabolism—HMOX1—atherosclerosis	6.6e-06	3.75e-05	CbGpPWpGaD
Bortezomib—PSMB8—Disease—IL6—atherosclerosis	6.58e-06	3.74e-05	CbGpPWpGaD
Bortezomib—CYP1A1—Metabolism—LPL—atherosclerosis	6.58e-06	3.74e-05	CbGpPWpGaD
Bortezomib—PSMB8—Immune System—AKT1—atherosclerosis	6.58e-06	3.74e-05	CbGpPWpGaD
Bortezomib—PSMB8—Gene Expression—AKT1—atherosclerosis	6.54e-06	3.71e-05	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—BGN—atherosclerosis	6.47e-06	3.67e-05	CbGpPWpGaD
Bortezomib—CYP1A1—Metabolism—GPX1—atherosclerosis	6.42e-06	3.65e-05	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—APOA5—atherosclerosis	6.41e-06	3.64e-05	CbGpPWpGaD
Bortezomib—PSMB1—Signaling Pathways—MAPK3—atherosclerosis	6.4e-06	3.63e-05	CbGpPWpGaD
Bortezomib—PSMB5—Signaling Pathways—MAPK3—atherosclerosis	6.4e-06	3.63e-05	CbGpPWpGaD
Bortezomib—PSMB2—Signaling Pathways—MAPK3—atherosclerosis	6.4e-06	3.63e-05	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism—SCARB1—atherosclerosis	6.36e-06	3.61e-05	CbGpPWpGaD
Bortezomib—CYP2C9—Metabolism of lipids and lipoproteins—PTGS2—atherosclerosis	6.34e-06	3.6e-05	CbGpPWpGaD
Bortezomib—CYP2C8—Metabolism—APOB—atherosclerosis	6.32e-06	3.59e-05	CbGpPWpGaD
Bortezomib—CYP2D6—Metabolism—ABCA1—atherosclerosis	6.32e-06	3.59e-05	CbGpPWpGaD
Bortezomib—PSMB8—Signaling Pathways—MAPK3—atherosclerosis	6.31e-06	3.58e-05	CbGpPWpGaD
Bortezomib—CYP2C9—Metabolism—ABCA1—atherosclerosis	6.26e-06	3.55e-05	CbGpPWpGaD
Bortezomib—CYP1A1—Metabolism—CD36—atherosclerosis	6.26e-06	3.55e-05	CbGpPWpGaD
Bortezomib—PSMB2—Signaling Pathways—TGFB1—atherosclerosis	6.21e-06	3.52e-05	CbGpPWpGaD
Bortezomib—PSMB1—Signaling Pathways—TGFB1—atherosclerosis	6.21e-06	3.52e-05	CbGpPWpGaD
Bortezomib—PSMB5—Signaling Pathways—TGFB1—atherosclerosis	6.21e-06	3.52e-05	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism of lipids and lipoproteins—ALB—atherosclerosis	6.19e-06	3.51e-05	CbGpPWpGaD
Bortezomib—PSMA1—Signaling Pathways—IL6—atherosclerosis	6.17e-06	3.5e-05	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—PLA2G1B—atherosclerosis	6.17e-06	3.5e-05	CbGpPWpGaD
Bortezomib—PSMB5—Disease—AKT1—atherosclerosis	6.16e-06	3.5e-05	CbGpPWpGaD
Bortezomib—PSMB2—Disease—AKT1—atherosclerosis	6.16e-06	3.5e-05	CbGpPWpGaD
Bortezomib—PSMB1—Disease—AKT1—atherosclerosis	6.16e-06	3.5e-05	CbGpPWpGaD
Bortezomib—CYP2C8—Metabolism—GSTM1—atherosclerosis	6.15e-06	3.49e-05	CbGpPWpGaD
Bortezomib—PSMD1—Signaling Pathways—IL6—atherosclerosis	6.14e-06	3.49e-05	CbGpPWpGaD
Bortezomib—PTGS1—Metabolism—ALB—atherosclerosis	6.14e-06	3.48e-05	CbGpPWpGaD
Bortezomib—PSMB8—Signaling Pathways—TGFB1—atherosclerosis	6.12e-06	3.47e-05	CbGpPWpGaD
Bortezomib—PSMD2—Signaling Pathways—IL6—atherosclerosis	6.11e-06	3.47e-05	CbGpPWpGaD
Bortezomib—PSMB8—Disease—AKT1—atherosclerosis	6.07e-06	3.45e-05	CbGpPWpGaD
Bortezomib—CYP2C8—Metabolism—LPL—atherosclerosis	6.04e-06	3.43e-05	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism—HMGCR—atherosclerosis	6e-06	3.41e-05	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—ALOX5—atherosclerosis	5.96e-06	3.38e-05	CbGpPWpGaD
Bortezomib—CYP1A1—Metabolism—MTHFR—atherosclerosis	5.93e-06	3.37e-05	CbGpPWpGaD
Bortezomib—CYP2C19—Metabolism—HMOX1—atherosclerosis	5.89e-06	3.34e-05	CbGpPWpGaD
Bortezomib—CYP2C8—Metabolism—GPX1—atherosclerosis	5.89e-06	3.34e-05	CbGpPWpGaD
Bortezomib—PTGS1—Metabolism—NOS3—atherosclerosis	5.87e-06	3.33e-05	CbGpPWpGaD
Bortezomib—CYP1A1—Metabolism—PPARA—atherosclerosis	5.82e-06	3.3e-05	CbGpPWpGaD
Bortezomib—CYP2C8—Metabolism—CD36—atherosclerosis	5.74e-06	3.26e-05	CbGpPWpGaD
Bortezomib—PSMA1—Signaling Pathways—AKT1—atherosclerosis	5.69e-06	3.23e-05	CbGpPWpGaD
Bortezomib—PSMD1—Signaling Pathways—AKT1—atherosclerosis	5.67e-06	3.22e-05	CbGpPWpGaD
Bortezomib—CYP2C19—Metabolism—APOB—atherosclerosis	5.64e-06	3.2e-05	CbGpPWpGaD
Bortezomib—PSMD2—Signaling Pathways—AKT1—atherosclerosis	5.64e-06	3.2e-05	CbGpPWpGaD
Bortezomib—CYP1A1—Metabolism—AGT—atherosclerosis	5.63e-06	3.2e-05	CbGpPWpGaD
Bortezomib—CYP1A1—Metabolism—APOE—atherosclerosis	5.52e-06	3.13e-05	CbGpPWpGaD
Bortezomib—CYP2C19—Metabolism—GSTM1—atherosclerosis	5.49e-06	3.12e-05	CbGpPWpGaD
Bortezomib—CYP1A1—Metabolism—CAV1—atherosclerosis	5.47e-06	3.1e-05	CbGpPWpGaD
Bortezomib—CYP1A1—Metabolism—APOA1—atherosclerosis	5.46e-06	3.1e-05	CbGpPWpGaD
Bortezomib—CYP2C8—Metabolism—MTHFR—atherosclerosis	5.44e-06	3.09e-05	CbGpPWpGaD
Bortezomib—CYP2D6—Metabolism—HMOX1—atherosclerosis	5.42e-06	3.08e-05	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism of lipids and lipoproteins—PTGS2—atherosclerosis	5.41e-06	3.07e-05	CbGpPWpGaD
Bortezomib—CYP2C19—Metabolism—LPL—atherosclerosis	5.39e-06	3.06e-05	CbGpPWpGaD
Bortezomib—CYP2C9—Metabolism—HMOX1—atherosclerosis	5.37e-06	3.05e-05	CbGpPWpGaD
Bortezomib—PTGS1—Metabolism—PTGS2—atherosclerosis	5.37e-06	3.05e-05	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism—ABCA1—atherosclerosis	5.35e-06	3.04e-05	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—NAMPT—atherosclerosis	5.34e-06	3.03e-05	CbGpPWpGaD
Bortezomib—CYP2C8—Metabolism—PPARA—atherosclerosis	5.33e-06	3.03e-05	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—LIPC—atherosclerosis	5.31e-06	3.01e-05	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—APOC3—atherosclerosis	5.28e-06	3e-05	CbGpPWpGaD
Bortezomib—CYP2C19—Metabolism—GPX1—atherosclerosis	5.26e-06	2.98e-05	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—LDLR—atherosclerosis	5.24e-06	2.98e-05	CbGpPWpGaD
Bortezomib—CYP2D6—Metabolism—APOB—atherosclerosis	5.19e-06	2.95e-05	CbGpPWpGaD
Bortezomib—CYP2C8—Metabolism—AGT—atherosclerosis	5.16e-06	2.93e-05	CbGpPWpGaD
Bortezomib—PSMB5—Metabolism—AKT1—atherosclerosis	5.16e-06	2.93e-05	CbGpPWpGaD
Bortezomib—PSMB1—Metabolism—AKT1—atherosclerosis	5.16e-06	2.93e-05	CbGpPWpGaD
Bortezomib—PSMB2—Metabolism—AKT1—atherosclerosis	5.16e-06	2.93e-05	CbGpPWpGaD
Bortezomib—CYP2C9—Metabolism—APOB—atherosclerosis	5.15e-06	2.92e-05	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—CETP—atherosclerosis	5.12e-06	2.91e-05	CbGpPWpGaD
Bortezomib—CYP2C19—Metabolism—CD36—atherosclerosis	5.12e-06	2.91e-05	CbGpPWpGaD
Bortezomib—PSMB8—Metabolism—AKT1—atherosclerosis	5.09e-06	2.89e-05	CbGpPWpGaD
Bortezomib—CYP2C8—Metabolism—APOE—atherosclerosis	5.06e-06	2.87e-05	CbGpPWpGaD
Bortezomib—CYP2D6—Metabolism—GSTM1—atherosclerosis	5.05e-06	2.87e-05	CbGpPWpGaD
Bortezomib—CYP2C8—Metabolism—CAV1—atherosclerosis	5.01e-06	2.85e-05	CbGpPWpGaD
Bortezomib—CYP2C9—Metabolism—GSTM1—atherosclerosis	5.01e-06	2.84e-05	CbGpPWpGaD
Bortezomib—CYP2C8—Metabolism—APOA1—atherosclerosis	5e-06	2.84e-05	CbGpPWpGaD
Bortezomib—CYP1A1—Metabolism—PIK3CG—atherosclerosis	4.98e-06	2.83e-05	CbGpPWpGaD
Bortezomib—CYP2D6—Metabolism—LPL—atherosclerosis	4.96e-06	2.81e-05	CbGpPWpGaD
Bortezomib—CYP2C9—Metabolism—LPL—atherosclerosis	4.91e-06	2.79e-05	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—SCARB1—atherosclerosis	4.91e-06	2.79e-05	CbGpPWpGaD
Bortezomib—CYP2C19—Metabolism—MTHFR—atherosclerosis	4.85e-06	2.75e-05	CbGpPWpGaD
Bortezomib—CYP2D6—Metabolism—GPX1—atherosclerosis	4.84e-06	2.74e-05	CbGpPWpGaD
Bortezomib—CYP1A1—Metabolism—PPARG—atherosclerosis	4.81e-06	2.73e-05	CbGpPWpGaD
Bortezomib—CYP2C9—Metabolism—GPX1—atherosclerosis	4.79e-06	2.72e-05	CbGpPWpGaD
Bortezomib—CYP2C19—Metabolism—PPARA—atherosclerosis	4.76e-06	2.7e-05	CbGpPWpGaD
Bortezomib—CYP1A1—Metabolism—INS—atherosclerosis	4.72e-06	2.68e-05	CbGpPWpGaD
Bortezomib—CYP2D6—Metabolism—CD36—atherosclerosis	4.71e-06	2.67e-05	CbGpPWpGaD
Bortezomib—PSMB5—Signaling Pathways—IL6—atherosclerosis	4.68e-06	2.66e-05	CbGpPWpGaD
Bortezomib—PSMB1—Signaling Pathways—IL6—atherosclerosis	4.68e-06	2.66e-05	CbGpPWpGaD
Bortezomib—PSMB2—Signaling Pathways—IL6—atherosclerosis	4.68e-06	2.66e-05	CbGpPWpGaD
Bortezomib—CYP2C9—Metabolism—CD36—atherosclerosis	4.67e-06	2.65e-05	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—HMGCR—atherosclerosis	4.63e-06	2.63e-05	CbGpPWpGaD
Bortezomib—PSMB8—Signaling Pathways—IL6—atherosclerosis	4.61e-06	2.62e-05	CbGpPWpGaD
Bortezomib—CYP2C19—Metabolism—AGT—atherosclerosis	4.61e-06	2.62e-05	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism—HMOX1—atherosclerosis	4.59e-06	2.61e-05	CbGpPWpGaD
Bortezomib—CYP2C8—Metabolism—PIK3CG—atherosclerosis	4.57e-06	2.59e-05	CbGpPWpGaD
Bortezomib—CYP2C19—Metabolism—APOE—atherosclerosis	4.52e-06	2.56e-05	CbGpPWpGaD
Bortezomib—CYP2C19—Metabolism—CAV1—atherosclerosis	4.47e-06	2.54e-05	CbGpPWpGaD
Bortezomib—CYP2C19—Metabolism—APOA1—atherosclerosis	4.46e-06	2.53e-05	CbGpPWpGaD
Bortezomib—CYP2D6—Metabolism—MTHFR—atherosclerosis	4.46e-06	2.53e-05	CbGpPWpGaD
Bortezomib—CYP2C9—Metabolism—MTHFR—atherosclerosis	4.42e-06	2.51e-05	CbGpPWpGaD
Bortezomib—CYP2C8—Metabolism—PPARG—atherosclerosis	4.41e-06	2.5e-05	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism—APOB—atherosclerosis	4.4e-06	2.5e-05	CbGpPWpGaD
Bortezomib—CYP2D6—Metabolism—PPARA—atherosclerosis	4.38e-06	2.49e-05	CbGpPWpGaD
Bortezomib—CYP2C9—Metabolism—PPARA—atherosclerosis	4.34e-06	2.46e-05	CbGpPWpGaD
Bortezomib—CYP2C8—Metabolism—INS—atherosclerosis	4.32e-06	2.45e-05	CbGpPWpGaD
Bortezomib—CYP1A1—Metabolism—ALB—atherosclerosis	4.32e-06	2.45e-05	CbGpPWpGaD
Bortezomib—PSMB1—Signaling Pathways—AKT1—atherosclerosis	4.31e-06	2.45e-05	CbGpPWpGaD
Bortezomib—PSMB5—Signaling Pathways—AKT1—atherosclerosis	4.31e-06	2.45e-05	CbGpPWpGaD
Bortezomib—PSMB2—Signaling Pathways—AKT1—atherosclerosis	4.31e-06	2.45e-05	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism—GSTM1—atherosclerosis	4.28e-06	2.43e-05	CbGpPWpGaD
Bortezomib—PSMB8—Signaling Pathways—AKT1—atherosclerosis	4.25e-06	2.42e-05	CbGpPWpGaD
Bortezomib—CYP2D6—Metabolism—AGT—atherosclerosis	4.24e-06	2.41e-05	CbGpPWpGaD
Bortezomib—CYP2C9—Metabolism—AGT—atherosclerosis	4.2e-06	2.39e-05	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism—LPL—atherosclerosis	4.2e-06	2.38e-05	CbGpPWpGaD
Bortezomib—CYP2D6—Metabolism—APOE—atherosclerosis	4.15e-06	2.36e-05	CbGpPWpGaD
Bortezomib—CYP1A1—Metabolism—NOS3—atherosclerosis	4.13e-06	2.35e-05	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—ABCA1—atherosclerosis	4.13e-06	2.34e-05	CbGpPWpGaD
Bortezomib—CYP2C9—Metabolism—APOE—atherosclerosis	4.12e-06	2.34e-05	CbGpPWpGaD
Bortezomib—CYP2D6—Metabolism—CAV1—atherosclerosis	4.12e-06	2.34e-05	CbGpPWpGaD
Bortezomib—CYP2D6—Metabolism—APOA1—atherosclerosis	4.11e-06	2.33e-05	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism—GPX1—atherosclerosis	4.1e-06	2.33e-05	CbGpPWpGaD
Bortezomib—CYP2C9—Metabolism—CAV1—atherosclerosis	4.08e-06	2.32e-05	CbGpPWpGaD
Bortezomib—CYP2C19—Metabolism—PIK3CG—atherosclerosis	4.08e-06	2.31e-05	CbGpPWpGaD
Bortezomib—CYP2C9—Metabolism—APOA1—atherosclerosis	4.07e-06	2.31e-05	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism—CD36—atherosclerosis	3.99e-06	2.26e-05	CbGpPWpGaD
Bortezomib—CYP2C8—Metabolism—ALB—atherosclerosis	3.96e-06	2.25e-05	CbGpPWpGaD
Bortezomib—CYP2C19—Metabolism—PPARG—atherosclerosis	3.93e-06	2.23e-05	CbGpPWpGaD
Bortezomib—CYP2C19—Metabolism—INS—atherosclerosis	3.86e-06	2.19e-05	CbGpPWpGaD
Bortezomib—CYP2C8—Metabolism—NOS3—atherosclerosis	3.79e-06	2.15e-05	CbGpPWpGaD
Bortezomib—CYP1A1—Metabolism—PTGS2—atherosclerosis	3.78e-06	2.15e-05	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism—MTHFR—atherosclerosis	3.78e-06	2.15e-05	CbGpPWpGaD
Bortezomib—CYP2D6—Metabolism—PIK3CG—atherosclerosis	3.75e-06	2.13e-05	CbGpPWpGaD
Bortezomib—CYP2C9—Metabolism—PIK3CG—atherosclerosis	3.72e-06	2.11e-05	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism—PPARA—atherosclerosis	3.71e-06	2.11e-05	CbGpPWpGaD
Bortezomib—CYP2D6—Metabolism—PPARG—atherosclerosis	3.62e-06	2.05e-05	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism—AGT—atherosclerosis	3.59e-06	2.04e-05	CbGpPWpGaD
Bortezomib—CYP2C9—Metabolism—PPARG—atherosclerosis	3.59e-06	2.04e-05	CbGpPWpGaD
Bortezomib—CYP2D6—Metabolism—INS—atherosclerosis	3.55e-06	2.01e-05	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—HMOX1—atherosclerosis	3.54e-06	2.01e-05	CbGpPWpGaD
Bortezomib—CYP2C19—Metabolism—ALB—atherosclerosis	3.54e-06	2.01e-05	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism—APOE—atherosclerosis	3.52e-06	2e-05	CbGpPWpGaD
Bortezomib—CYP2C9—Metabolism—INS—atherosclerosis	3.52e-06	2e-05	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism—CAV1—atherosclerosis	3.49e-06	1.98e-05	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism—APOA1—atherosclerosis	3.48e-06	1.98e-05	CbGpPWpGaD
Bortezomib—CYP2C8—Metabolism—PTGS2—atherosclerosis	3.47e-06	1.97e-05	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—APOB—atherosclerosis	3.39e-06	1.93e-05	CbGpPWpGaD
Bortezomib—CYP2C19—Metabolism—NOS3—atherosclerosis	3.38e-06	1.92e-05	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—GSTM1—atherosclerosis	3.3e-06	1.87e-05	CbGpPWpGaD
Bortezomib—CYP2D6—Metabolism—ALB—atherosclerosis	3.25e-06	1.85e-05	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—LPL—atherosclerosis	3.24e-06	1.84e-05	CbGpPWpGaD
Bortezomib—CYP2C9—Metabolism—ALB—atherosclerosis	3.23e-06	1.83e-05	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism—PIK3CG—atherosclerosis	3.18e-06	1.8e-05	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—GPX1—atherosclerosis	3.16e-06	1.79e-05	CbGpPWpGaD
Bortezomib—CYP2D6—Metabolism—NOS3—atherosclerosis	3.11e-06	1.77e-05	CbGpPWpGaD
Bortezomib—CYP2C19—Metabolism—PTGS2—atherosclerosis	3.09e-06	1.76e-05	CbGpPWpGaD
Bortezomib—CYP2C9—Metabolism—NOS3—atherosclerosis	3.09e-06	1.75e-05	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—CD36—atherosclerosis	3.08e-06	1.75e-05	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism—PPARG—atherosclerosis	3.07e-06	1.74e-05	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism—INS—atherosclerosis	3.01e-06	1.71e-05	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—MTHFR—atherosclerosis	2.92e-06	1.66e-05	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—PPARA—atherosclerosis	2.86e-06	1.62e-05	CbGpPWpGaD
Bortezomib—CYP2D6—Metabolism—PTGS2—atherosclerosis	2.85e-06	1.62e-05	CbGpPWpGaD
Bortezomib—CYP2C9—Metabolism—PTGS2—atherosclerosis	2.82e-06	1.6e-05	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—AGT—atherosclerosis	2.77e-06	1.57e-05	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism—ALB—atherosclerosis	2.76e-06	1.56e-05	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—APOE—atherosclerosis	2.72e-06	1.54e-05	CbGpPWpGaD
Bortezomib—PTGS1—Metabolism—AKT1—atherosclerosis	2.7e-06	1.53e-05	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—CAV1—atherosclerosis	2.69e-06	1.53e-05	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—APOA1—atherosclerosis	2.68e-06	1.52e-05	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism—NOS3—atherosclerosis	2.64e-06	1.5e-05	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—PIK3CG—atherosclerosis	2.45e-06	1.39e-05	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism—PTGS2—atherosclerosis	2.41e-06	1.37e-05	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—PPARG—atherosclerosis	2.37e-06	1.34e-05	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—INS—atherosclerosis	2.32e-06	1.32e-05	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—ALB—atherosclerosis	2.13e-06	1.21e-05	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—NOS3—atherosclerosis	2.03e-06	1.16e-05	CbGpPWpGaD
Bortezomib—CYP1A1—Metabolism—AKT1—atherosclerosis	1.9e-06	1.08e-05	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—PTGS2—atherosclerosis	1.86e-06	1.06e-05	CbGpPWpGaD
Bortezomib—CYP2C8—Metabolism—AKT1—atherosclerosis	1.74e-06	9.89e-06	CbGpPWpGaD
Bortezomib—CYP2C19—Metabolism—AKT1—atherosclerosis	1.56e-06	8.83e-06	CbGpPWpGaD
Bortezomib—CYP2D6—Metabolism—AKT1—atherosclerosis	1.43e-06	8.12e-06	CbGpPWpGaD
Bortezomib—CYP2C9—Metabolism—AKT1—atherosclerosis	1.42e-06	8.05e-06	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism—AKT1—atherosclerosis	1.21e-06	6.88e-06	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—AKT1—atherosclerosis	9.35e-07	5.31e-06	CbGpPWpGaD
